Kornimate/medical-research-clean huggingface dataset:
the itap study for veterans

Conditions: Insomnia; Alcohol; Harmful Use

Summary: this project aims to evaluate improvement of insomnia as a mechanism of improvement in alcohol use outcomes.

more than half of returning veterans who screen positive for hazardous drinking report clinically significant symptoms of insomnia. in turn, insomnia symptoms have been associated with increased risk of alcohol-related problems, perhaps due to insomnia-related impairments in executive functioning, negative emotionality, and craving. the proposed project aims to examine improvements in insomnia as a mechanism for improvement in alcohol use among heavy-drinking veterans with insomnia. forty-four returning veterans who report heavy drinking (≥4/5 drinks per occasion for women/men) and have insomnia based on dsm-5 and research diagnostic criteria will participate in a randomized pilot trial. participants will be randomly assigned to receive personalized normative alcohol feedback in the context of one of two treatment conditions: cbt-i (n = 22) or a sleep hygiene education control (sh; n = 22). outcomes will be assessed at the end of the active intervention period (6 weeks), mid-treatment (after 3 sessions), and at 3 months post-intervention. outcomes of interest include insomnia severity, total wake time, sleep quality, drinking quantity/frequency, alcohol-related consequences, executive functioning, negative affect, emotion regulation, craving for alcohol, and use of alcohol as a sleep aid.

Eligibility criteria:
inclusion criteria: * veteran deployed for military service after september 11, 2001 * 1+ heavy drinking episode (4/5+ drinks in 2 hours for women/men) in past 30 days * dsm-5 and research diagnostic criteria for insomnia disorder exclusion criteria: * inability to provide informed consent * cognitive impairment * contraindications for cbt-i (mania or seizure disorder) * untreated sleep disorder requiring more than behavioral treatment for insomnia * engagement in overnight shift work at baseline * care of a child under 1 year of age * severe or untreated psychiatric disorder that requires immediate clinical attention * current behavioral treatment for insomnia or alcohol use * initiation of sleep medication in the past 6 weeks

Keywords: alcohol drinking sleep insomnia veteran
the sentinel registry

Conditions: Aortic Valve Disease; Transcatheter Aortic Valve Implantation; Transcatheter Aortic Valve Replacement

Summary: this registry is to evaluate procedural outcomes and safety outcomes of cerebral protection devices during transfemoral tavr in real-world clinical practice. the data from this registry will be compared with the extracted data from the tp tavr registry(nct038262664) using propensity score matching.


Eligibility criteria:
inclusion criteria: * age 19 and more * undergoing tavr with the use of sentinel embolic protection device * higher risk of cerebrovascular embolic events (any of the followings) 1. bicuspid aortic valve 2. calcified lesion or atherosclerosis in the ascending aorta and/or aortic arch 3. heavy calcified aortic valve (ca. volume \> 500) 4. chronic kidney disease 5. prior stroke 6. stroke risk is strongly anticipated by attending physicians * compatible carotid and brachiocephalic artery anatomy for sentinel device as determined by multi-slice computed tomography scan or equivalent imaging modality * agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate institutional review board/ethical committee of the respective clinical site. exclusion criteria: * vasculature in the right extremity precluding radial or brachial access * excessive tortuosity in the right radial/brachial/subclavian artery preventing sentinel system access and insertion * inadequate circulation to the right extremity as evidenced by signs of artery occlusion (modified allen's test) or absence of radial/brachial pulse * hemodialysis shunt, graft, or arterio-venous fistula involving the upper extremity vasculature * symptomatic or asymptomatic severe occlusive carotid disease requiring concomitant carotid endarterectomy/stenting * undergone carotid stenting or carotid endarterectomy within the previous 6 weeks * concurrent medical condition with a life expectancy of less than 1 year

Keywords: cerebral protection
the combination of immunotherapy and neoadjuvant short-course radiotherapy in early rectal cancer

Conditions: Early Low Rectal Cancer

Summary: the study evaluates the combination of immunotherapy of pd-1 antibody and neoadjuvant short-course radiotherapy in early low rectal cancer. a total of 34 patients will receive 5\*5gy short-course radiotherapy, followed by 4 cycles of capecitabine plus oxaliplatin (capox) chemotherapy and pd-1 antibody, finally receive the local excision(tem) or total mesorectal excision (tme). the rate of complete response (ccr+pcr), organ retention rate, long-term prognosis, and adverse effects will be analyzed.


Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, female and male 2. pathological confirmed adenocarcinoma 3. clinical stage t1-3bn0, tumor maximum diameter less than 4cm 4. the distance from anal verge less than 5 cm 5. without distance metastases 6. kps \>=70 7. with good compliance 8. microsatellite repair status is mss/pmmr 9. without previous anti-cancer therapy or immunotherapy 10. signed the inform consent exclusion criteria: 1. pregnancy or breast-feeding women 2. pathological confirmed signet ring cell carcinoma 3. clinical stage t1n0 and can be resected locally 4. history of other malignancies within 5 years 5. serious medical illness, such as severe mental disorders, cardiac disease, uncontrolled infection, etc. 6. immunodeficiency disease or long-term using of immunosuppressive agents 7. baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10\^9/l, hb≥90g/l, plt≥100×10\^9/l, alt/ast ≤2.5 uln, cr≤ 1 uln 8. dpd deficiency 9. allergic to any component of the therapy
adductor canal block: continuous infusion versus automatic intermittent bolus

Conditions: Injury of Anterior Cruciate Ligament

Summary: the aim of this prospective, randomized , blinded study is to compare two different infusion techniques (continuous vs intermittent automatic bolus) to assess the effects of postoperative analgesia after day-case anterior cruciate ligament (acl) reconstruction.


Eligibility criteria:
inclusion criteria: * age above 18 years old * american society of anesthesiology (asa) physical status i-ii * signed informed consensus exclusion criteria: * asa \>ii * unstable neurological disease * diabetic mellitus (dm) type i-ii * allergy to used drugs * opioid chronic treatment * consensus refusal or not valid * anticoagulant therapy * postoperative intensive care required
retrospective chart review of first-time opsumit® (macitentan) users in the united states

Conditions: Pulmonary Arterial Hypertension

Summary: the opsumit users registry (opus; nct02126943) was developed to characterize the safety profile of opsumit and to describe clinical characteristics and outcomes of patients newly treated with opsumit in the post-marketing setting. it is expected that the recruitment target of the opus registry cannot be achieved within the planned time period (5000 opsumit new users by october 2018). the orpheus study is designed to supplement the opus registry with retrospectively identified first-time opsumit users in order to achieve the desired sample size.


Eligibility criteria:
inclusion criteria: * patients who initiated opsumit for the first time between 19 october 2013 and 31 december 2016 (inclusive) * patients whose medical charts are available for data collection exclusion criteria: * patient participation in the opus registry * patient participation in any clinical trial involving opsumit treatment or macitentan investigational product
snags in mechanical neck pain

Conditions: Neck Pain

Summary: neck pain is second largest cause of disability worldwide. chronic neck pain prevalence is 14% which is somewhat higher in females as compared to males. in india reported prevalence is 6%. therapeutically, neck pain is managed by physiotherapists using rest, stretching and strengthening exercises, educating patient, and intense proprioception and positional exercises.

to determine the evidences for the efficacy of snags in the management of mechanical neck pain. 100 patients \[age group 25-45 yrs\] who were diagnosed with neck pain, with onset ˃1-3 months (chronic) were randomly assigned to group a receiving conventional physiotherapy plus snags and group b receiving conventional physiotherapy plus ultrasound. subjects in-group a that received conventional physiotherapy plus snags showed greater improvement in pain and range of motion compared with the conventional physiotherapy plus ultrasound group on 2nd week compared with pretreatment. the result of study suggests that both snags and ultrasound groups improves the symptoms of neck pain. ultrasound group improved the pain symptoms but was too small to reach satisfactory outcome for patients. based on these results conventional physiotherapy plus snags should be the treatment of choice for neck pain rather than conventional physiotherapy plus ultrasound .

Eligibility criteria:
inclusion criteria * age group between 20- 45 years. * both gender male and female. * individuals having localized pain or stiffness in spine or both combined b/w c3 to c7 without upper limbs radiculopathy. * pain reported on vas score ˃3 in neck region. * patients agree to sign written consent form. exclusion criteria patients were excluded if they were diagnosed with following conditions for ˃6 months: * t.b, carcinoma, heart disease, osteoporosis. * neural disorders due to pivd. * any trauma or localized infection in neck region. * upper mnd, cervical stenosis, metabolic diseases in bone and joint. * hyper flexibility * open sores, * ongoing radiotherapy, chemotherapy, steroid therapy or anticoagulants. * psychiatric diseases such as phobia/obsession, depression. * allergy to hot pack * patients with history of surgery in cervical spine region with in a year.
intravitreal dexamethasone implant for refractory diabetic macular edema:

Conditions: Diabetic Macular Edema

Summary: we have been using dex for refractory dme for a long time (since 2016). thus, we are sharing our results , evaluating both anatomical and functional outcomes of dex therapy for refractory dme.

our study aims at evaluating both anatomical and functional outcomes of dex therapy for cases of refractory dme, with both a single injection, and /or with retreatments.

Eligibility criteria:
inclusion criteria: * • age: 16 or older (adults) * sex: both * ntdme with cmt \>300 u * \< 10% reduction in cmt (than previous treatment) * \< 50 u reduction in cmt (than previous treatment) * worsening of bcva \> 1 line on e chart. * duration since previous treatment is: 3 months with dex, 1 month with anti-vegf * pseudophakic eyes * npdr , prp-treated pdr exclusion criteria: * • phakic eyes * uncontrolled glaucoma (iop \> 24 mmhg, or cup disc ratio 0.8 or more) * herpetic viral infection. * untreated pdr
measure of plasma tissue factor to predict a venous thromboembolism in primitive cancer of lung

Conditions: Cancer of Lung

Summary: the aim of the study is to evaluate if the plasma activity of the tissue factor at the time of the diagnosis of a lung cancer, before any treatment, or after the treatment of induction (surgery or two first cures of chemotherapy), can be a predictive factor of venous thromboembolism disease in the year which follows the diagnosis, independently of the other parameters.


Eligibility criteria:
inclusion criteria: * patients of more than 18 years old * patients with cancer of lung diagnosis carried for less than 2 months and which were not handled yet, either by surgery or by chemotherapy, or by radiotherapy * patients whose life expectancy is considered 3-month-old a superior * patients having given writed consent * patients affiliated to a national insurance scheme or benefiting from such a diet * patients having received a treatment (processing) anticoagulating in preventive dose if this treatment was stopped at least 3 days before the 1st taking or patients not receiving an anticoagulating treatment (in case of curative treatment, the latter was before arrested at least 3 months exclusion criteria: * patients having a hepatic disease with coagulation disorders * patients under anticoagulants with dose guardian in 3 months preceding the study or presenting an active infection * patients having a history of other cancer considered as cured and diagnosed for less than 5 years (with the exception of the patients operated for an in situ carcinoma of the neck of the womb or the patients having undergone the excision of a squamous-cell carcinoma)
circulating tumor cells and mpmri for non-invasive diagnosis of prostate cancer(cmndpc)

Conditions: Prostate Cancer

Summary: this trial is a prospective, multicentre, diagnostic study. this study aims to evaluation the early diagnostic ability of circulating tumor cells plus multimodal mri for prostate cancer.

this trial is a prospective, multicentre, diagnostic study. this study aims to evaluation the early diagnostic ability of circulating tumor cells plus multimodal mri for prostate cancer. we will enroll 808 men with clinical suspicion of prostate cancer due to higher level psa（\>4ng/ml）or other examination abnormal. all the participants will receive prostate biopsy，the circulating tumor cells（ctcs）will be detected before biopsy. this study will evaluate the diagnostic ability of ctcs+mri and ctcs+mri+psa，including sensitivity, specificity, predictive values, diagnostic accuracy and receiver operating curves（roc）.

Eligibility criteria:
inclusion criteria: 1. no family history of prostate cancer; 2. men ≥ 50 years； 3. tpsa level of 4-10 ng/ml, and fpsa/tpsa\<0.16; 4. tpsa level of \>10 ng/ml； 5. with abnomal mpmri、pet/ct、trus or dre; 6. fully understand the clinical trial protocol and sign the informed consent; exclusion criteria: 1. not meet all of the inclusion criteria or any single inclusion criteria； 2. previous diagnosis of prostate carcinoma ; 3. symptomatic of acute prostatitis; 4. local anesthetic allergy patients; 5. cannot tolerate prostate biopsy or has contraindication to biopsy; 6. patients judged by the investigator to be unsuitable to participate in the clinical trial;

Keywords: circulating tumor cells multimodal mri prostate cancer diagnosis
impact of ait on allergic rhinitis and asthma

Conditions: Allergy; Respiratory Disease

Summary: the study will assess the effectiveness of ait treatment in real clinical practice in germany.

allergic rhinitis (ar) affects 23-30% of the european population and is associated with a major burden on public health. ar and asthma frequently coexist, and may both be caused by allergen exposure. while the efficacy of ait, i.e. reduce symptoms and medication use in patients with ar and asthma, has been demonstrated in several randomized clinical trials, little is known about the use and effectiveness of ait in real world clinical practice. this study is a retrospective database study that uses real-world data from germany. the study population consists of ar patients with and without asthma treated with ait and matched controls not treated with ait. information about the patients and treatments will be obtained from the 'bkk german sickness fund database' from 2007 until 2017.

Eligibility criteria:
inclusion criteria for the ait cohort: * at least two index-ait prescriptions during the first fu-year * at least one confirmed ar diagnosis during the study period * continuous enrollment (no gaps in insurance time-defined by days) for 12 months before the index event (in the pre-index period) * continuous enrollment (no gaps in insurance time-defined by days) for at least 12 months after the index event (in the post-index period) inclusion criteria for the control cohort: - for the control groups, the same inclusion criteria will apply, with the exception of inclusion criterion 1, i.e. controls have not received ait before baseline. exclusion criteria: - ait prescription 12 months before the index event (in the pre-index period) for the ait treatment group
innovative physiotherapy in stroke rehabilitation

Conditions: Stroke, Ischemic; Chronic Stroke Survivors

Summary: this study reports a single-case rehabilitation program for a chronic stroke patient focusing on innovative physiotherapy techniques. over six weeks, the patient will undergo combined treatments including vestibular rehabilitation therapy, ultrasound therapy, and functional hand therapy using saebo devices. the goal is to improve motor functions and daily living independence. this report aims to share clinical insights and outcomes to support stroke rehabilitation practices.

this single-case clinical report presents a comprehensive rehabilitation program for a stroke patient over a period of six weeks. the intervention consists of three main components: 1. vestibular rehabilitation therapy (vrt): exercises aimed at improving ocular motor control, balance, and vestibulo-ocular reflex through specific eye movements and walking patterns, progressing in difficulty over time. 2. ultrasound therapy: application of low-frequency portable ultrasound to targeted muscle groups to reduce spasticity and promote muscle relaxation, performed in prone or side-lying positions. 3. functional hand rehabilitation: use of saebostim go and saebo glove devices to reduce spasticity in upper limb muscles and enhance hand function through electrical stimulation and active-assisted exercises. throughout the program, treatment sessions are conducted three times weekly, each lasting two hours. outcomes related to motor improvement, spasticity reduction, and functional independence are monitored and evaluated using descriptive statistics and time-series analysis. the purpose of this report is to provide detailed clinical insights into the application of combined innovative physiotherapy methods in stroke rehabilitation and to highlight their potential benefits.

Eligibility criteria:
inclusion criteria: * adults aged 18 years and older. * diagnosis of chronic ischemic stroke (more than 6 months post-stroke). * presence of motor dysfunction, balance impairment, or gait difficulties related to stroke. * willingness and ability to participate in a comprehensive rehabilitation program involving physical therapy and device-assisted interventions (e.g., saebostim go, saebo glove). exclusion criteria: * presence of uncontrolled systemic diseases or active infections that would interfere with rehabilitation. * severe psychiatric disorders that would impede participation. * contraindications to the use of physical therapy devices or interventions used in the study. * severe orthopedic conditions that preclude participation in the rehabilitation program.

Keywords: chronic stroke saebo ultrasound therapy vestibular training stroke rehabilitation balance case report functional independence
safety and efficacy of idec-152 in the treatment of chronic lymphocytic leukemia (cll)

Conditions: Chronic Lymphocytic Leukemia

Summary: to determine what side effects and what clinical effects if any the administration of this investigational product, idec-152 (an antibody against cd23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the cll patient population.


Eligibility criteria:
inclusion criteria: * signed irb-approved informed consent. * greater than 18 years of age * proof of cd23+ cll or small lymphocytic lymphoma (sll) * progressive disease after at least 1 course of chemotherapy * acceptable hematologic status, liver function, renal function, and pulmonary function * patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment exclusion criteria: * previous exposure to idec-152 or other anti-cd23 antibodies * presence of hiv infection or aids * serious nonmalignant disease * active uncontrolled bacterial, viral or fungal infections. * clinically active autoimmune disease * pregnant or currently breast feeding

Keywords: chronic lymphoblastic leukemia leukemia, lymphoblastic, chronic chronic lymphocytic leukemia cll
femto-flap versus sbk flap,predictability and variability

Conditions: Refractive Errors; Refractive Surgery

Summary: laser insitu keratomileusis (lasik) has become the most popular procedure for refractive error correction. lasik flap creation is the first and critical step during lasik surgery because of its consensual effect on a residual stromal bed, corneal biomechanics, and hence the future risk of ectasia⁴.in the current study, we compared the visumax fsl flap thickness predictability, accuracy, and variability with the flap created by single-use moria sbk microkeratome.

flap creation techniques have evolved from the old manual procedure of mechanical microkeratome to the automated one with the use of microkeratome and more recently to femto-laser procedure using a variety of machines. authors have reported that the primary vision nearly the same despite the different methods of flap creation in the first 6 months post laser vision correction. others have reported that a thinner flap is associated with better primary vision and refractive outcomes. sbk (sub bowman keratomileusis), is a procedure in which the lasik flap is thinner, and has the advantage of leaving a sufficient stromal bed for safer excimer laser ablation. there are five types of femtosecond laser that were already approved currently for lasik flap creation. the zeiss (visumax fsl ) which has been used in the current study uses 1043 nm, a repetition rate of 500 khz, and 220-580 femtoseconds pulse duration. each laser pulse produces micro-photo disruption in the tissue, contiguous few microns sized photo disruptions will create a continuous cut in the corneal tissue at precise preset position and depth. in the current study, the visumax flap thickness predictability, accuracy, and variability were compared with the flap created by a single-use moria sbk microkeratome.

Eligibility criteria:
inclusion criteria: * having refractive errors range from -2 to- 6 ds and from -1 to -3.00dc. * they have stable refraction for at least one year prior to surgery. * normal topography by placido-scheimpflug (sirius, costruzione strumenti oftalmici, florence, italia) and normal corneal epithelial map by anterior segment-oct system (optovue inc, fremont, california, usa) exclusion criteria: 1. patient with suspicious topography and or corneal epithelial map. 2. patient with corneal pachymetry below 500µm. 3. patients who have a history of previous ocular surgery or trauma. 4. patient with a current or previous history of herpes simplex or herpes zoster. 5. patient with severe dry eye, diabetes, thyrotoxicosis, and connective tissue diseases. 6. patient with combined ocular diseases like retinal dystrophy or glaucoma. 7. patient with a history of contact lenses use was meant to stop the use of soft contact lenses for at least 2 weeks or hard type for at least 4 weeks before topography and other investigations were done. 8. patient who refrains from the required follow-up visits; have been excluded from the study. -

Keywords: visumax femtolasik sub bowman keratomileusis(sbk) lasik